Moderna Settles Patent Dispute with Roivant for Up to $2.25 Billion

Moderna has agreed to pay Roivant up to $2.25 billion to settle a patent lawsuit related to mRNA vaccine technology, resolving a significant legal challenge. This settlement highlights ongoing patent disputes that could impact the vaccine's commercial landscape and Moderna's market strategy. Watch for potential shifts in vaccine pricing and innovation efforts as the settlement's long-term implications unfold.